Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics (IPSC) reported operational updates reflecting continued development of its iPSC-derived cell therapy pipeline and recent acquisition activity. The company disclosed 86,322,071 shares outstanding at June 30, 2025 versus 85,836,429 at December 31, 2024. Century completed the acquisition of Clade, issuing 3,741,646 common shares at close and recording holdback shares of up to 793,687 subject to indemnification adjustments. Contingent consideration at closing included a fair-value amount of $2,600 plus a potential Clade milestone valued at $8,883, and a possible milestone payment of $10,000 payable in cash, shares, or combination.
The filing outlines program progress and capabilities including lead candidate CNTY-101, preclinical programs from Clade, and additional CAR-iT candidates (CNTY-308, CNTY-341) using the company’s Allo-Evasion™ and iPSC platforms. The company reported prior ATM sales of 4,084,502 shares for net proceeds of $17,829 in the six months ended June 30, 2024 and no ATM sales in the six months ended June 30, 2025. Quarter-over-quarter operating expense shifts include G&A of $7.8M versus $8.3M in the prior-year quarter and mixed R&D and facility cost changes driven by staff reductions, consolidation of lab operations, and completion of a manufacturing campaign under the FCDI collaboration.